Objective: To probe into the application rationality of ribonucleic acid for injection Ⅱ in children. Methods: A total of 295 medical records of ribonucleic acid for injection Ⅱ were randomly extracted from Children’s Hospital of Hebei Province from Jun. 2018 to May 2019. Combined with the drug instructions

age and body mass of the children

the indications

dosage

frequency and drug combination were statistically analyzed to preliminarily discuss the application rationality of ribonucleic acid for injection Ⅱ in children. Results: The results of drug application evaluation indicated that the application rationality was relatively high

and the scoring rates were respectively drug frequency (100%)

solvent selection (100%)

drug combination (98.50%)

indications (86.20%)

immune function examination (83.60%) and dosage (79.50%). The results of drug utilization analysis showed that the children drug utilization index (CDUI) decreased with the increase of body mass

with more severe excessive use in the low body mass group and insufficient use in the high body mass group. Conclusion: The clinical application of ribonucleic acid for injection Ⅱ in children should be standardized to promote the rational drug application